Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab + Palliative RT in Stage IV Melanoma
NCT01449279Phase 2Completed
- Sponsor
- Stanford University
- Start
- Oct 2011
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by Stanford University. Primary endpoint: Percentage of Patients Experiencing Serious Adverse Events (SAEs) at 4 months. Started Oct 2011; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01449279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01449279.